On Thursday, Perseon Corp (NASDAQ:PRSN)’s shares dwindled -26.83%, and closed at $0.300, as Perseon Corp (NASDAQ:PRSN), Pyrexar Medical started operations after concluding the attainment of hyperthermia assets held by Perseon (PRSN), formerly BSD Medical (BSDM). This attainment comprises substantially all hyperthermia assets, products, services and related intellectual property.
Medical device industry veteran Mark Falkowski has been named Chief Executive Officer bringing to Pyrexar more than 30 years of successful executive leadership experience with prominent medical companies like GE Healthcare, Imatron, Carestream and OEC/Diasonics.
Pyrexar will be presenting and exhibiting at the forthcoming Society for Thermal Medicine Annual Meeting in Orlando, FL (April 14-17, 2015).
PYREXAR MEDICAL: With the attainment of BSD Medical assets, Pyrexar Medical takes its place as pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established distribution and support networks in the US, Europe and Asia. PYREXAR HyperThermia (PYREXAR HT) treatments raise the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity of healthy tissues.
Perseon Corporation: a life sciences corporation, develops, manufactures, markets, and services medical systems to treat cancer and benign diseases using heat therapy. The corporation offers MicroThermX microwave ablation system that comprises a microwave generator, single-patient-use disposable antennas with cooling circuit, and a thermistor based temperature monitoring system; and employs precision-guided microwave energy to ablate diseased soft tissue.
Cytosorbents Corp (NASDAQ:CTSO)’s shares dropped -14.52%, and settled at $7.71, during the last trading session on Thursday, after Cytosorbents Corp (NASDAQ:CTSO), provides an operational summary and states financial results for the fiscal year ending December 31, 2014.
Highlights for the Year Ending December 31, 2014:
- Total proceed for 2014 was $4.1 million, which comprises both product sales and grant revenue, contrast to total proceed of $2.4 million for 2013
- Product gross margins were 63% in 2014, as contrast to 61% in 2013
- Product proceeds for the fourth quarter of 2014 were about $871,000, an raise of 177% over the fourth quarter of 2013 product proceeds of about $314,000
- Up-listed to the NASDAQ Capital Market in December 2014, providing an ideal platform from which to broadly communicate our exciting story to potential investors
- Ranked #11 amongst Forbes’ Best-Performing Biotech Stocks of 2014 with a total return of 218.4%
- Received the GREAT Tech Award from Prince William, Duke of Cambridge, also sponsored by the United Kingdom Trade & Investment and the British Consulate General New York, the Beacon of Light Award by the New Jersey Technology Council, and the Export Achievement Award from the U.S. Department of Commerce and the International Trade Administration.
CytoSorbents Corporation, a critical care focused immunotherapy corporation, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology.
At the end of Thursday’s trade, SeaChange International (NASDAQ:SEAC)’s shares dipped -13.13%, and closed at $6.95, as SeaChange International (NASDAQ:SEAC), stated fourth quarter fiscal 2015 proceed of $31.3 million and U.S. GAAP loss from operations of $5.3 million, or $0.16 per basic share for the fourth quarter of fiscal 2015, contrast to fourth quarter fiscal 2014 proceed of $35.6 million and U.S. GAAP operating loss of $0.9 million, or $0.03 per basic share. The Corporation’s U.S. GAAP fourth quarter fiscal 2015 results comprise non-GAAP charges of $3.6 million, which comprised primarily of severance and other restructuring costs, stock-based compensation, amortization of intangible assets from preceding attainments, and professional fees from divestitures and litigation.
For the full fiscal year ended January 31, 2015, the Corporation posted proceeds of $115.4 million and U.S. GAAP operating loss of $26.5 million, or $0.81 per basic share, contrast to proceeds of $146.3 million and U.S. GAAP operating loss of $1.6 million, or $0.05 per basic share, from ongoing operations in the same preceding period. The Corporation posted a non-GAAP loss from operations for fiscal 2015 of $13.8 million, or $0.42 per basic share, contrast to an $8.4 million operating revenue, or $0.25 per fully diluted share, from ongoing operations for the same preceding period.
SeaChange International: provides multi-screen videos products and services that facilitate the aggregation, licensing, administration, and distribution of video and television advertisements to cable system operators, and telecommunications and media companies worldwide.
Solar3D Inc (NASDAQ:SLTD), ended its Thursday’s trading session with -10.98% loss, and closed at $4.46, as Solar3D Inc (NASDAQ:SLTD), stated financial results for the year ended December 31, 2014.
Financial Highlights:
- Proceed of $20.2 million in 2014, driven by the attainment of SUNworks
- Cash and cash equivalents were over $0.4 million on December 31, 2014 as compared to $10,422 a year earlier
- For the year ended December 31, 2014, the Corporation stated operating revenue of $311,072, as contrast to an operating loss of $1.1 million for the same period of 2013
- The Corporation stated a net loss of $24.9 million or ($2.15) per diluted share for the year 2014, contrast to a net loss of $3.8 million, or ($0.59) per diluted share for 2013
- The entire net loss for the full year 2014 is the result of non-cash accounting expenses counting changes in the fair value of derivative liabilities, non-cash interest expense on convertible notes and losses on settlement of debt
- Adjusted EBITDA of $1.0 million for the year ended December 31, 2014
- Solar3D’s Adjusted Net Revenue of $277,985 for 2014 as compared to an Adjusted Net Loss of $1,081,181 for 2013
- Total assets were $6.7 million at December 31, 2014 contrast to $47,179 at December 31, 2013.
Solar3D: provides photo voltaic based power systems for the residential, commercial, and agricultural markets in the United States. It also designs, finances, integrates, and manages systems ranging in size from 2 kilowatt for residential loads to multi megawatt systems for larger commercial projects.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
